INFO SHEET: TechAccess Subscriptions
TechAccess Subscriptions provide access to Berkeley Lights’ revolutionary workflows no matter
the size of your lab, your customer base, or budget.
Webinar: Abveris on Lessons Learned from 2+ Years of Discovering Functional Antibodies on the Beacon
At PEGS EU 2021, Abveris CEO Tracey Mullen shared a few important lessons learned through using the Beacon system for antibody discovery. She discussed how the Berkeley Lights Platform has enabled Abveris to focus on deeply screening their antibodies upstream and only pulling forward the most qualified and functionally relevant antibodies for re-expression.
APP NOTE: Discover Lead Molecules Against Difficult Targets in 1 Week with Opto® Plasma B Discovery 4.0
Find out how the Opto Plasma B Discovery 4.0 workflow can be used to access broad plasma cell diversity, rapidly down-select lead candidates with functional profiling, and sequence and re-express >1,000 functionally characterized antibodies in 1 week.
Webinar: Opto™ Plasma B Discovery 4.0 Fireside Chat
Join members of our Opto Plasma B Discovery 4.0 development team for a panel discussion about our latest antibody discovery workflow.
Customer Spotlight: Amgen on the Berkeley Lights Platform
Philip Tagari, VP Therapeutic Discovery, Amgen, discusses how the Berkeley Lights’ platform has transformed the way Amgen approaches antibody discovery and cell line development.
Brochure: Get to the Clinic First with Best-In-Class Antibody Therapeutics
Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows Pharma to succeed against difficult targets and deliver best-in-class antibody therapeutics.
Brochure: Lead Molecules Against Any Target. At Record Pace.
Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows CROs to scale their business and rapidly deliver lead molecules even against difficult targets.
Webinar: Rapid Discovery of Functional Antibodies for SARS-CoV-2
Dr. Robert Carnahan, Ph.D., discusses how the Beacon system helped enable the rapid discovery functional antibodies against SARS-CoV-2.
Customer Spotlight: Genovac on Antibody Discovery
Find out how Genovac is delivering 10-fold more lead candidates against difficult targets.
Webinar: Looking to the Future: What’s next in Antibody Therapeutics
At the 2021 AE&T EU conference, Tracey Mullens, CEO of Abveris, and Brian Walters, CEO of Genovac, joined John Proctor, SVP Antibody Therapeutics, for a discussion about the evolving landscape of antibody therapeutics, the technologies they have turned to address today’s complex targets, and how they are preparing for tomorrow’s challenges.
Webinar: Accelerating Discovery and Development of Antibody Therapeutics
Hear from BLI experts Renee Tobias and Anupam Singhal about the unique benefits to leveraging a single platform for both the identification of promising candidates and the production of leading therapeutic molecules.
Datasheet: Opto™ Plasma B Discovery 4.0
Review workflow overview and representative results.
App Note: Discover Lead Molecules Against Difficult Targets Inaccessible by Hybridoma Methods
Download this application note to learn about how the Opto™ Plasma B Discovery workflow increases hit recovery for difficult membrane-bound targets and provides access to greater sequence diversity when compared to traditional hybridoma methods.
Product Tour: The Opto™ Plasma B Discovery 4.0 Workflow
Antibody expert, Anupam Singhal, PhD, does a 10-minute walkthrough of how the Opto™ Plasma B Discover workflow makes it possible to accelerate lead molecule discovery against difficult targets.
Webinar: Tackle Difficult Targets by Accessing Broad B Cell Diversity
Watch our presentation at AE&T Digital Week, hosted with Genovac, to hear how the Beacon system is making it possible to find 10 times more lead candidates than hybridoma in just days.
Webinar: A Beacon for Rapid Antibody Discovery against Difficult Targets
Panelists from Genovac, will present case studies of how they have leveraged their core genetic immunization technology and the Beacon optofluidic system to rapidly discover antibodies against challenging targets, such as GPCRs, from a variety of different animal species.
Application Note: Rapid High-Resolution Screening of Plasma B Cells to Identify Antibody Lead Candidates
Explore case studies for the rapid discovery of antibodies against challenging targets.
Customer Spotlight: Abveris on Antibody Discovery
Find out how Abveris is transforming their antibody discovery processes with the Beacon® optofluidic system.